. | . |
Serbia starts vaccination with Chinese-made Sinopharm by AFP Staff Writers Belgrade (AFP) Jan 19, 2021 Serbia launched on Tuesday a mass Covid-19 vaccination campaign and became the first European country to use the Chinese-made Sinopharm jab. "It is the only way to return to normal life," said Health Minister Zlatibor Loncar, the first who received the vaccine. "These are all very safe vaccines," Loncar said as the state-run RTS television carried his vaccination live at the virology institute in Belgrade. There is no reason for concern regarding their safety, he stressed. Serbia received on Saturday one million doses of the Sinopharm vaccine. It is the third coronavirus jab used by the Balkan nation, after Pfizer-BioNTech and Russia's Sputnik V. President Aleksandar Vucic announced earlier Tuesday the start of the mass vaccination campaign and said jabs will be administered at some 300 locations in Serbia's biggest cities. Vucic is to be inoculated with the Sinopharm vaccine at the weekend. Serbia secured nearly 1,055,000 doses of the three jabs and agreed on the delivery of additional six million doses, Prime Minister Ana Brnabic said. AFP data based on official sources show Serbia is the first European country to administer the Sinopharm vaccine. The European Union-candidate country, which has also close economic and political ties with Moscow and Beijing, started vaccination with Pfizer-BioNTech jabs on December 24 -- with Brnabic receiving it. It later imported Russian Sputnik V jabs. Sinopharm says its vaccine is 79 percent effective against the novel coronavirus. Another Chinese-made jab, Sinovac's CoronaVac, was rolled out in Turkey last week. Serbia has registered nearly 380,000 infections and more than 3,700 deaths from the novel coronavirus. By mid-January, some 20,500 people -- residents of retirement homes and health sector employees -- have been vaccinated in the country, official figures show.
Chinese city rushes to build massive Covid-19 quarantine centre Beijing (AFP) Jan 19, 2021 Thousands of prefabricated rooms fill a vast field on the outskirts of China's Shijiazhuang city as construction crews work around the clock to erect a large quarantine facility to curb the city's growing Covid-19 outbreak. China has largely brought the virus under control even as the rest of the world struggles with mounting deaths and overburdened hospitals. But a spate of small, localised outbreaks has prompted Chinese officials to order mass testing, strict lockdowns and to prepare to move ... read more
|
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |